Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 22 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Selexipag Tablets, along with a period of shared exclusivity. The approval allows Zydus to market various strengths of Selexipag Tablets, which are used to treat pulmonary arterial hypertension. This approval marks a significant milestone as Zydus was among the first applicants to submit a complete application for these tablets. The drug is set to be manufactured at Zydus's facility in Ahmedabad, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 22, 2022, titled "Zydus receives final approval and 180 days shared exclusivity from the USFDA for Selexipag Tablets".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases